These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 9640232

  • 1. Pharmacokinetics of cisplatin with and without amifostine in tumour-bearing nude mice.
    Korst AE, Boven E, van der Sterre ML, Fichtinger-Schepman AM, van der Vijgh WJ.
    Eur J Cancer; 1998 Feb; 34(3):412-6. PubMed ID: 9640232
    [Abstract] [Full Text] [Related]

  • 2. Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.
    Korst AE, Boven E, van der Sterre ML, Fichtinger-Schepman AM, van der Vijgh WJ.
    Br J Cancer; 1997 Feb; 75(10):1439-46. PubMed ID: 9166935
    [Abstract] [Full Text] [Related]

  • 3. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
    Boven E, Verschraagen M, Hulscher TM, Erkelens CA, Hausheer FH, Pinedo HM, van der Vijgh WJ.
    Eur J Cancer; 2002 May; 38(8):1148-56. PubMed ID: 12008205
    [Abstract] [Full Text] [Related]

  • 4. Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo.
    van der Vijgh WJ, Korst AE.
    Eur J Cancer; 1996 May; 32A Suppl 4():S26-30. PubMed ID: 8976819
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
    Bonetti A, Apostoli P, Zaninelli M, Pavanel F, Colombatti M, Cetto GL, Franceschi T, Sperotto L, Leone R.
    Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
    Peng B, Tilby MJ, English MW, Price L, Pearson AD, Boddy AV, Newell DR.
    Br J Cancer; 1997 Nov; 76(11):1466-73. PubMed ID: 9400943
    [Abstract] [Full Text] [Related]

  • 16. A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
    Gradishar WJ, Stephenson P, Glover DJ, Neuberg DS, Moore MR, Windschitl HE, Piel I, Abeloff MD.
    Cancer; 2001 Nov 15; 92(10):2517-22. PubMed ID: 11745184
    [Abstract] [Full Text] [Related]

  • 17. High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics.
    Ekborn A, Hansson J, Ehrsson H, Eksborg S, Wallin I, Wagenius G, Laurell G.
    Laryngoscope; 2004 Sep 15; 114(9):1660-7. PubMed ID: 15475801
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients.
    Zackrisson AL, Malmström H, Peterson C.
    Eur J Clin Pharmacol; 2002 May 15; 58(2):103-8. PubMed ID: 12012141
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.